]>
IRCT2017041533448N1 IRCT 2017-05-24 Vice chancellor for research, Zahedan University of Medical Sciences Evaluation of treatment options of central serous chorioretinopathy Evaluation of comparative effect of intravitreal bevasizumab on visual acuity and central macular thickness in patient with central serous chorioretinopathy 2017-05-31 anticipated 30 Complete https://irct.ir/trial/25791 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. N/A Central Serous Chorioretinoathy. Intervention 1: Control group : without any intervention , just close abservation ( 15 patinets ). Intervention 2: Intervention group : 1.25 mg intravireal injection of bevasizumab , one time intravitreal injection ( 15 patinets ).
public Mohammad Reza Shahraki
Dr .Hesabi Squere , Zahedan
Zahedan Iran (Islamic Republic of) +98 54 3329 5725 m_Shahrakim@zaums.ac.ir Vice chancellor for research, Zahedan University of Medical Sciences scientific Alireza Maleki
Shahid Mottahari St , Zahedan
Zahedan Iran (Islamic Republic of) +98 543233551 a_r_maleki@yahoo.com Alzahra Eye Hospital Zahedan Iran (Islamic Republic of) Inclusion criteria: Patients with visual loss (2 lines Snellen chart or more) and in scan (the thickness of the central part of the macula greater than 250 microns) diagnosis of central serous chorioretinopathy they laid is. Exclusion criteria: Patient with visual loss with pathological retinal diseases other than Central serous retinopathy and diabetic retinopathy and hypertensive retinopathy and retinal dystrophies and patients who do not have the desire to enter the study. no limit no limit Both H35.7 Central Serous Chorioretinopathy Diagnosis Treatment - Drugs Control group : without any intervention , just close abservation ( 15 patinets ) Intervention group : 1.25 mg intravireal injection of bevasizumab , one time intravitreal injection ( 15 patinets ) Visual acuity. Timepoint: Before start the study and 2 months and 4 months after intervention. Method of measurement: Snellen acuity chart. Central Maclar Thickness. Timepoint: Before start the study and 2 months and 4 months after intervention. Method of measurement: Optical Coherence Tomography. Vice chancellor for research, Zahedan University of Medical Sciences Approved 2017-03-07 Ethics Committee of Zahedan University of Medical Sciene Dr.Hesabi Squre Zahedan Iran (Islamic Republic of)